Literature DB >> 32861446

Long-term morbidity and follow-up after choledochal malformation surgery; A plea for a quality of life study.

R H de Kleine1, A Ten Hove2, J B F Hulscher3.   

Abstract

Much about the aetiology, pathophysiology, natural course and optimal treatment of choledochal malformation remains under debate. Surgeons continuously strive to optimize their roles in the management of choledochal malformation. Nowadays the standard treatment is complete cyst excision followed by Roux-en-Y hepaticojejunostomy, be it via a laparotomy, laparoscopy or robot-assisted procedure. Whatever surgical endeavor is undertaken, it will be a major operation, with significant morbidity. It is important to realize that especially in asymptomatic cases, this is considered prophylactic surgery, aimed at preventing symptoms but even more important the development of malignancy later in life. A clear overview of long-term outcomes is therefore necessary. This paper aims to review the long-term outcomes after surgery for choledochal malformation. We will focus on biliary complications such as cholangitis, the development of malignancy and quality of life. We will try and identify factors related to a worse outcome. Finally, we make a plea for a large scale study into quality and course of life after resection of a choledochal malformation, to help patients, parents and their treating physicians to come to a well-balanced decision regarding the treatment of a choledochal malformation.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Cholangiocarcinoma; Cholangitis; Choledochal malformation; Follow-up; Quality of life; Review

Mesh:

Year:  2020        PMID: 32861446     DOI: 10.1016/j.sempedsurg.2020.150942

Source DB:  PubMed          Journal:  Semin Pediatr Surg        ISSN: 1055-8586            Impact factor:   2.754


  1 in total

1.  Usefulness of hepatobiliary scintigraphy for predicting late complications in patients with choledochal cysts.

Authors:  Yunosuke Kawaguchi; Keita Terui; Shugo Komatsu; Mitsuyuki Nakata; Ryohei Shibata; Hiroko Yoshizawa; Tomoya Hirokawa; Erika Nakatani; Tomoro Hishiki
Journal:  Pediatr Surg Int       Date:  2022-09-20       Impact factor: 2.003

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.